Sensus Healthcare (SRTS) Scheduled to Post Quarterly Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS) is set to announce its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. Sensus Healthcare had a return on equity of 13.46% and a net margin of 18.27%. The company had revenue of $9.24 million during the quarter, compared to analysts’ expectations of $7.00 million. During the same period in the prior year, the business posted ($0.02) EPS. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sensus Healthcare Price Performance

Sensus Healthcare stock opened at $6.69 on Thursday. The firm has a market capitalization of $109.65 million, a price-to-earnings ratio of 16.32 and a beta of 1.04. The company’s 50 day simple moving average is $6.26 and its 200 day simple moving average is $5.77. Sensus Healthcare has a fifty-two week low of $1.79 and a fifty-two week high of $7.18.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Roth Capital raised shares of Sensus Healthcare to a “strong-buy” rating in a research report on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Sensus Healthcare in a research note on Monday, August 12th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.